Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Abaloparatide
A PTHrP-based anabolic peptide for osteoporosis, with labelling extended to men at high fracture risk.
Teriparatide
A parathyroid-hormone fragment that builds bone — one of the few anabolic osteoporosis treatments.
How far human research has progressed
Abaloparatide
Approved osteoporosis medicineTeriparatide
Long-approved osteoporosis medicineClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Abaloparatide
Not separately assessed; see the full profile.Teriparatide
Not separately assessed; see the full profile.Human research context
Abaloparatide
Approved osteoporosis medicineTeriparatide
Long-approved osteoporosis medicineHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Abaloparatide
Teriparatide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Abaloparatide
Teriparatide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Abaloparatide
Teriparatide
Regulatory status (legal position, not proof it works)
Abaloparatide
Named regulators: FDA (US)
FDA-approved (Tymlos) for osteoporosis in postmenopausal women and, in updated labelling, to increase bone density in men with osteoporosis at high fracture risk. Indication-specific.
Teriparatide
Named regulators: FDA (US)
Approved for osteoporosis in patients at high fracture risk, with indications varying by label and region. Indication-specific.
Common claims
Abaloparatide
- · Reduces fracture risk and increases bone density in high-risk osteoporosis
Teriparatide
- · Reduces fracture risk in high-risk osteoporosis
- · Builds new bone rather than only slowing loss
How settled our evidence rating is
Abaloparatide
Teriparatide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Abaloparatide
Rodent osteosarcoma findings drive class-level precautionary labelling; a human risk has not been established. Mechanistic precaution, not demonstrated human harm.Teriparatide
Rat studies found osteosarcoma at exposures far above human dosing, driving precautionary labelling. Post-marketing surveillance in humans has not established the same risk, but the precaution shapes how the drug is used.What this adds up to, in plain English
Abaloparatide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Teriparatide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation